Wassana Yantasee, PhD, MBA: President and CEO
Wassana Yantasee earned a doctorate in Chemical Engineering and a Master of Business Administration from Oregon State University. From 2001-2008, she worked as a scientist at Pacific Northwest National Laboratory (DoE National Lab). She is currently a professor with tenure in Biomedical Engineering at Oregon Health and Science University, where she is recognized as an Oregon Nanomedicine Signature Researcher. Professor Yantasee specializes in drug delivery and nanomedicine with 20 years of experience working with mesoporous silica nanoparticles and their biointerfaces. She has served as the principal investigator for several NIH awards and as a scientific reviewer in over 30 panels for the NIH and DoD. She founded PDX Pharmaceuticals in 2010 and has built values to the company by creating new intellectual properties using non-dilutive funding from the NIH (continuously since 2012).
Worapol Ngamcherdtrakul, PhD: Principal Scientist and Chief Operating Officer (COO)
Dr. Ngamcherdtrakul joined PDX Pharmaceuticals in 2015. He received his PhD in Biomedical Engineering from Oregon Health & Science University. The focus of his PhD dissertation was to develop a mesoporous silica nanoparticle into a carrier for siRNA delivery to treat breast cancer. At PDX Pharma, he leads the design, development, and optimization of nanoparticle platform to co-deliver drug, siRNA, and immunotherapy for treatment of multiple types of cancer and skin diseases. He is the contact PI of PDX Pharm’s ongoing SBIR grants from the National Institute of Health.
Moataz Reda, PhD: Scientist
PhD in Biomedical Engineering from Oregon Health & Science University
Sherif Reda, PhD: Scientist
Sherif Reda joined PDX Pharmaceuticals in 2020. He has several years of research experience in various fields including physiology, molecular biology, genetic engineering, and physics. Sherif graduated with a doctorate in Integrative Physiology and Neuroscience from Washington State University in 2019, where he was a first author on five peer-reviewed publications and received a medical research scholarship for his dissertation work. At PDX Pharmaceuticals, he utilizes his expertise in experimental design, data analysis, and technical writing to accelerate the path of our nanoparticle platform to the clinics.
B.S. in Biochemistry from University of Oregon
B.S. in Molecular Biology and Biochemistry from Oregon State University
B.S. in Chemistry from University of Minnesota
B.A. in Chemistry from University of Chicago
Members of Yantasee lab at the department of Biomedical Engineering at Oregon Health and Science University.
PDX Pharmaceuticals has been in close collaboration with the OHSU Center for Spatial Systems Biomedicine and the Knight Cancer Institute for the development of a siRNA-nanoparticle platform for breast cancer therapies under two fast-track phase I/II SBIR awards (total budget of $3M) from the NCI. The OHSU team consists of an internationally renowned cancer systems biology researcher, Prof. Joe Gray, PhD. Dr. Gordon Mills, a leading scientist in precision medicine, serves on our scientific advisory board. Multiple experts serve as consultants to PDX Pharmaceuticals (Table 1).
Table 1. Advisory/Consultant Panel of PDX Pharmaceuticals
|Gordon Mills, MD, Ph.D.||Professor and Director of Precision Oncology for the OHSU Knight Cancer Institute||Clinical precision oncology|
|Matthew Taylor, MD||Lead of Phase I clinical trial/KCI of OHSU||Clinical trial phase I protocols including IRB, enrollment, treatment, and efficacy and safety monitoring procedures|
|Shiuh-Wen Luoh, MD, Ph.D.||Oncologist/OHSU||Standard treatment regimens for HER2+ breast cancer (dosing, efficacy, adverse effects)|
|Sancy Leachman, MD, PhD||Professor and Chair, Department of Dermatology, OHSU||Melanoma and skin diseases|
|Jeremy Heidel||Informulate LLC||CMC, manufacturing, and IND-enabling studies|